311 results about "Acetylcysteine" patented technology

An amino acid composition with high nutrition supporting effect is composed of acetylcysteine, acetyltyrosine and tryptophan in weight ratio of (0.81-2): (0.81-2): (0.9-1.6).

The invention relates to an andrographolide derivative, which has the structure as shown in a general formula I: wherein, R1, R2 and R3 are the same or different hydrogen, substituted or non-substituted organic acid radical, inorganic acid radical, alkyl, aryl or heteroaryl, while at least one of R1, R2 and R3 is R-lipoic acid or S-lipoic acid or the mixture of R-lipoic acid and S-lipoic acid or the corresponding dihydrolipoic acid or acetylcysteine radical of R-lipoic acid or S-lipoic acid; the derivative has good anti-tumor effect, and the derivative can cause apoptosis of tumor cells, directly eliminate gram positive bacteria, staphylococcus aureus and sensitivities MRSA5676 and MRSA5677, inhibit the QS system of gram negative bacteria and pseudomonas aeruginosa and inhibit and damage the formation of the bio-film of pseudomonas aeruginosa; the product has prominent hypoplycemic effect and is suitable for the preparation of the medicines that can cure cancers, inflammations, diabetes mellitus and bacterial and viral infection.

The present invention relates to N-acetylcysteine compositions and methods for treating inflammation and redox imbalance in acute exacerbations of inflammatory lung disease.

Provided are hair processing agents capable of permanent waving hair even at a neutral to weakly acidic pH range that causes less irritation to the skin, and hair processing agents in which an unpleasant odor is masked. Hair processing agents contain at least one compound represented by the formula (2). Hair processing agents contain a compound of the formula (2) and at least one compound (ii) selected from thioglycolic acid, thiolactic acid, cysteine, acetylcysteine, cysteamine, acylcysteamine, salts thereof and ester derivatives thereof. Hair processing agents contain a compound of the formula (2), a surfactant and water, and are emulsified. Hair processing agents contain a compound of the formula (2) and a specific perfume. wherein X is a structure selected from —O—, —S—, —NH— and —NR¹—; R¹ is an alkyl group of 1 to 6 carbon atoms; Y is an oxygen atom or a sulfur atom; in the formula (1), Z is a divalent organic residue having at least one mercapto group; in the formula (2), R is a divalent organic residue optionally having a mercapto group; and R² is a hydrogen atom or an alkyl group of 1 to 6 carbon atoms.

The invention discloses a specific culture medium for a lung tumor organ and a stentless 3D culturing method. The specific culture medium is prepared from the following components: FBS, double antibody, N-2, Noggin, B-27, EGF, FGF-10, Y-27632, A 83-01, SB202190, N-acetylcysteine, HEPES, Glutamax, IGF-1, hydrocortisone and Advanced DMEM/F12. The culturing method comprises the following steps: adding a tumor cell into a low serum culture medium, re-suspending the tumor cell, inoculating the tumor cell into a culture vessel, adding the specific culture medium into the culture vessel, changing thespecific culture medium once a day, and performing culturing until an organoid is formed. According to the culture medium and culturing method, a tumor organoid can quickly generate, can be stably cultured for a long time, is regular in spheroid form and has uniform and controllable size, and the heterogeneity of a tumor tissue of a patient can be well maintained in vitro.

The invention discloses a medicinal composition containing dimeticone/simethicone. The composition is mainly prepared from the following raw material medicaments in portion by weight: 1 to 1,000 portions of acetylcysteine or pharmaceutically acceptable salt thereof, and 1 to 500 portions of the dimeticone/simethicone. The composition can be prepared into various pharmaceutically acceptable preparations; and the composition can be applied to gastrointestinal endoscopy and treatment or an adjuvant drug administered before imaging examination, and compared with the acetylcysteine or the dimeticone or simethicone which is in single use at the same dosage, the composition has stronger defrothing effect, and stronger grume removal effect, so that the composition can effectively improve the visual definition of examination and treatment, reduce misdiagnosis and missed diagnosis, and improve effectiveness of diagnosis and treatment, contributes to early diagnosis discovery of digestive tract diseases, and has wide application prospect.

The invention provides a method for separating and measuring acetylcysteine enantiomers. In the method, before acetylcysteine is added in a chromatographic column, a derivatization reagent is used to perform derivatization, wherein the derivatization reagent is N(alpha)-(5-fluoro-2,4-dinitrophenyl)-L-amino acid compound. The method for separation and measurement combines the high performance liquid chromatography (HPLC) or high performance liquid chromatography-mass spectrum (HPLC-MS), and the used chromatographic column uses octadecylsilane chemically bonded silica as filler. The method for separation and measurement comprises the following steps: (1) taking acetylcysteine or a preparation with acetylcysteine, dissolving in low-concentration acid solution, adjusting the pH value of the mixed solution to 6.0-8.0 with alkaline solution to obtain a sample solution for testing; (2) mixing the acetylcysteine solution with 1mol/L of carbonate solution, adding N(alpha)-(5-fluoro-2,4-dinitrophenyl)-L-amino acid compound to mix evenly; (3) reacting the solution obtained by the step (2) at 40-60 DEG C in a dark place, adding hydrochloric acid solution after the reaction; (4) adding the solution obtained by the step (3) in a drying solution with the prestored phosphorus pentoxide and potassium hydroxide, adding phosphate buffer solution-acetonitrile, dissolving residues through ultrasonic treatment, filtering to obtain filtrate which is used as a testing solution; and (5) adopting HPLC or HPLC-MS to separate and measure the testing solution prepared by the step (4).

The invention discloses an acetylcysteine granule and a preparation method thereof, which belong to the new technical field of pharmaceutical preparation, and relates to a new composition of the acetylcysteine granule and the perpetration technology thereof. In the new composition and the preparation technology thereof, the granule mainly consists of acetylcysteine, acrylic resin, mannitol, aspartame and orange essence, and weight ratio of the main constituents is 10:1-50:2-200:0-1:0-1. After being coated with the acrylic resin, the acetylcysteine is mixed with the dry mannitol granule, the aspartame and the orange essence to prepare the acetylcysteine granule; and the prepared acetylcysteine granule has obviously improved stability in wet environment, and the taste of the acetylcysteine granule is greatly improved.

Disclosed are pharmaceutical compositions comprising immediate release and sustained release formulations of 5-aminosalicylic acid, or a pharmaceutically acceptable salt or ester thereof, and/or N-acetylcysteine, or a pharmaceutically acceptable salt or ester thereof, for release in the lower gastrointestinal tract.

The present invention provides a culture medium and a culture method for colorectal cancer organoids. The culture medium comprises a basic culture medium Advanced DMEM/F12, specific additive factors and sterile water; wherein a mass ratio of the basic culture medium Advanced DMEM/F12 to the sterile water is 99:1; and the specific additive factors comprise B27 without vitamin A, N-acetylcysteine, EGF, Noggin, R-spondin 1, Wnt3a, CHIR99021, thiazovivin, Gastrin I, a penicillin-streptomycin mixture and Primocin. The culture medium is used to culture the colorectal cancer organoids, can maintain morphological structures and genetic characteristics of primary tissues, effectively reduces risks of microbial contamination in colorectal cancer culture, and improves success rate and survival rate of colorectal cancer organoid culture.

The invention discloses an exfoliative cell sap base preserving fluid, a method thereof for flaking and a kit. The exfoliative cell sap preserving fluid comprises the following components by massic volume percentage: 3.8-4.2% of paraformaldehyde, 0.8-1.5% of N-methyl-N-cyclohexyl-2-amino-3,5-bromhexine, 0.8-1.5% of glacial acetic acid, 0.1-0.2% of acetylcysteine, 0.75-0.85% of sodium chloride, 0.01-0.03% of potassium chloride, 0.12-0.15% of disodium hydrogen phosphate, 0.025-0.03% of monopotassium phosphate, and the balance of water; and pH is regulated to 7.2-7.8. The exfoliative cell sap base preserving fluid is small in shrinking to the exfoliative cell, and suitable for storage for a long time; the cell coated by the mucus in the sample is successfully separated, the positive cell stacking and loss are avoided, and the effective cell number is improved; and the preserving fluid can be used for observing whether the occult blood symptom is existent.

The invention provides a culture medium for stomach cancer organs and a culture method. The culture medium comprises a basic culture medium 1640, specific addition factors and sterile water, wherein the mass ratio of the basic culture medium 1640 to the sterile water is 99:1; and the specific addition factors comprise B27 without vitamin A, N-acetylcysteine, EGFs (epidermal growth factors), Noggin, R-spondin 1, Wnt3a, CHIR99021, thiazovivin, Gastrin I, valproic acid, a penicillin and streptomycin mixed liquid, amphotericin B and Primocin. The culture medium can be adopted to culture the stomach cancer organs, morphology structures and gene characteristics of primary tissue can be maintained, the risk of microorganism pollution in stomach cancer culture can be effectively reduced, and the success rate and the survival rate of stomach cancer organ culture can be increased.

The invention belongs to the field of a medicine preparation and relates to an inhalant acetylcysteine solution and a preparation method of the inhalant acetylcysteine solution. Physiological seawater is added into the solution, so that the sensitization of the acetylcysteine solution is effectively reduced.

The invention relates to a method for detecting acetylcysteine and related substances thereof. The method adopts a high performance liquid chromatography, wherein the chromatographic condition is that styrene-divinylbenzene copolymer type superpolymer chromatographic column, namely MKF-RP-MH is 4 to 10 mu meters and (100-300)*(8.0-4.0) millimeters (I.D.); the volume ratio of phosphate buffer (pH is between 2 and 5) with mobile phase compositions of 0.01-0.05 mol/L to acetonitrile is 80-95:20-5; the flowing speed is between 0.8 and 1.2 mL/min; the detecting wavelength detected by an ultraviolet detector is 210nm; and the sample size is between 10 and 20 mu liters. The method does not use ionpairreagent, overcomes the defects that ODS column detecting method does not have acid resistance or low organic phase resistance when detecting the acetylcysteine.

The invention relates to a pharmaceutical composition for reducing homocysteine, which comprises the following components: 1) an officinal dosage of folic acid or pharmaceutical salts thereof; 2) an officinal dosage of vitamin B12 or pharmaceutical salts thereof; 3) an officinal dosage of creatine or pharmaceutical salts thereof; and 4) pharmaceutical carriers or excipients. The composition further comprises one or more than one of betaine, VB6, N-acetylcysteine, and riboflavin. The invention also relates to application of the pharmaceutical composition in preparing drugs for reducing the homocysteine as well as the application thereof in preparing the drugs for treating life bodies suffered from hyperhomocysteinemia. The pharmaceutical composition belongs to the field of pharmacy.

An acetylcysteine composition in the form of powder injection with high solubility and stability is prepared from acetylcysteine and pH regulate chosen from sodium dicarbonate, sodium carbonate, sodium hydroxide and bisodium dicarbonate in weight ratio of 1: (0.25-1). Its preparing process is also disclosed.

PCT No. PCT/ES97/00113 Sec. 371 Date Jan. 12, 1999 Sec. 102(e) Date Jan. 12, 1999 PCT Filed May 7, 1997 PCT Pub. No. WO97/42358 PCT Pub. Date Nov. 13, 1997The process comprises: (A) obtainment of N-acetyl-cysteine from L-cystine, by means of the following steps: (i) acetylation of L-cystine to produce N-acetyl-cystine; (ii) electroreduction and desalination by electrodialysis of the N-acetyl-cystine thus produced to give N-acetyl-cysteine; or (B) obtainment of N-acetyl-cysteine from L-cystine, by means of the following steps: (i) acetylation and desalination of L-cystine to produce N-acetyl-cystine; (ii) electroreduction of N-acetyl-cystine which may or may not come from the preceding step (i) to produce N-acetyl-cysteine; (C) obtainment of N-acetyl-cysteine from L-cystine by means of the following steps: (i) electroreduction of L-cystine to produce L-cysteine; (ii) acetylation and desalination by electrodialysis of L-cysteine, which may or may not come from the preceding step (i) to produce N-acetyl-cysteine. The N-acetyl-cysteine thus obtained has important uses in the pharmaceutical sector.

The invention discloses an acetylcysteine effervescent tablet and a preparation method thereof, and belongs to the technical field of medicines. The effervescent tablet comprises acetylcysteine, an alkali source, a sweetening agent, a filler and a lubricant. The effervescent tablet has the advantages of being less in excipient varieties, good in external properties, good in stability, simple in process, and easy in large-scale production, and the like.